Lumos Net Tangible Assets from 2010 to 2024
| LUMO Stock | USD 4.31 0.02 0.46% |
Net Tangible Assets | First Reported 2011-09-30 | Previous Quarter 59.6 M | Current Value 43.7 M | Quarterly Volatility 52.8 M |
Check Lumos Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lumos Pharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 41.8 K, Interest Expense of 671.3 K or Selling General Administrative of 18.6 M, as well as many indicators such as Price To Sales Ratio of 12.0, Dividend Yield of 0.0 or PTB Ratio of 1.0. Lumos financial statements analysis is a perfect complement when working with Lumos Pharma Valuation or Volatility modules.
Lumos | Net Tangible Assets |
Latest Lumos Pharma's Net Tangible Assets Growth Pattern
Below is the plot of the Net Tangible Assets of Lumos Pharma over the last few years. It is the total assets of a company minus any intangible assets such as patents, copyrights, and goodwill; it represents the physical assets of a company. Lumos Pharma's Net Tangible Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Lumos Pharma's overall financial position and show how it may be relating to other accounts over time.
| Net Tangible Assets | 10 Years Trend |
|
Net Tangible Assets |
| Timeline |
Lumos Net Tangible Assets Regression Statistics
| Arithmetic Mean | 96,996,293 | |
| Geometric Mean | 81,064,568 | |
| Coefficient Of Variation | 56.42 | |
| Mean Deviation | 44,027,966 | |
| Median | 88,977,000 | |
| Standard Deviation | 54,722,805 | |
| Sample Variance | 2994.6T | |
| Range | 177.8M | |
| R-Value | 0.15 | |
| Mean Square Error | 3152.8T | |
| R-Squared | 0.02 | |
| Significance | 0.59 | |
| Slope | 1,830,461 | |
| Total Sum of Squares | 41924.2T |
Lumos Net Tangible Assets History
About Lumos Pharma Financial Statements
Lumos Pharma investors utilize fundamental indicators, such as Net Tangible Assets, to predict how Lumos Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Net Tangible Assets | 68.5 M | 104.9 M |
Check out the analysis of Lumos Pharma Correlation against competitors. To learn how to invest in Lumos Stock, please use our How to Invest in Lumos Pharma guide.You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lumos Pharma. If investors know Lumos will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lumos Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.28) | Revenue Per Share 0.27 | Quarterly Revenue Growth 102.714 | Return On Assets (0.70) | Return On Equity (1.73) |
The market value of Lumos Pharma is measured differently than its book value, which is the value of Lumos that is recorded on the company's balance sheet. Investors also form their own opinion of Lumos Pharma's value that differs from its market value or its book value, called intrinsic value, which is Lumos Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lumos Pharma's market value can be influenced by many factors that don't directly affect Lumos Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lumos Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lumos Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lumos Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.